US2007237819A1PendingUtilityA1

Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor

71
Individually held — no corporate assignee on recordPriority: Sep 20, 1993Filed: Jun 4, 2007Published: Oct 11, 2007
Est. expirySep 20, 2013(expired)· nominal 20-yr term from priority
Inventors:David J. Bova
A61K 9/2077A61P 3/10A61P 7/00A61P 3/06A61K 31/44A61K 9/2054A61K 9/2027A61K 31/455
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . (canceled)  
     
     
         4 . (canceled)  
     
     
         5 . (canceled)  
     
     
         6 . (canceled)  
     
     
         7 . (canceled)  
     
     
         8 . (canceled)  
     
     
         9 . (canceled)  
     
     
         10 . (canceled)  
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . A method of treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with about 500 mg to about 3000 mg of nicotinic acid once per day after food, wherein said nicotinic acid is combined with at least one pharmaceutically acceptable carrier to form sustained release oral solid dosage form.    
     
     
         14 . The method according to  claim 13 , wherein the release rate of nicotinic acid is from about 2.0% per hour to about 25% per hour.  
     
     
         15 . The method according to  claim 13 , wherein said nicotinic acid is dosed in a form of a tablet prepared by formulating the nicotinic acid with from 5 to about 50 parts by weight of hydroxypropylmethylcellulose per 100 parts by weight of tablet.  
     
     
         16 . The method according to  claim 13 , wherein said nicotinic acid is dosed in a form of a tablet containing from about 1 to 4 parts by weight of binder per 100 parts by weight of tablet.  
     
     
         17 . The method according to  claim 16 , wherein the binder is polyvinyl pyrrolidone.  
     
     
         18 . The method according to  claim 13 , wherein said nicotinic acid is dosed in the form of a tablet comprising from about 0.5 to about 2.5 parts by weight of a lubricating agent per 100 parts by weight of tablet.  
     
     
         19 . The method according to  claim 18 , wherein the lubricating agent is stearic acid.  
     
     
         20 . The method according to  claim 13 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         21 . A method of treating hyperlipidemia in a hyperlipidemic, the method comprising the step of: 
 dosing the hyperlipidemic with a composition comprising about 500 mg to about 3000 mg of nicotinic acid once per day after food, wherein said of nicotinic acid composition is sustained release oral solid dosage comprising IIPMC, a binder, and a lubricant.    
     
     
         22 . The method according to  claim 21 , wherein the binder is povidone.  
     
     
         23 . The method according to  claim 21 , wherein the lubricant is stearic acid.  
     
     
         24 . The method according to  claim 21 , wherein the binder is povidone and the lubricant is stearic acid.  
     
     
         25 . The method according to  claim 21 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         26 . The method according to claims  13  or  21 , wherein the dosage form contains about 500 mg nicotinic acid.  
     
     
         27 . The method according to claims  13  or  21 , wherein the dosage form contains about 750 mg nicotinic acid.  
     
     
         28 . The method according to claims  13  or  21 , wherein the dosage form contains about 1000 mg nicotinic acid.  
     
     
         29 . The method according to claims  13  or  21 , wherein the dosage form contains about 1500 mg nicotinic acid.  
     
     
         30 . The method according to claims  13  or  21 , wherein the dosage form contains about 2000 mg nicotinic acid.  
     
     
         31 . The method according to claims  13  or  21 , wherein the dosage form contains about 3000 mg nicotinic acid.  
     
     
         32 . The method according to  claim 26 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         33 . The method according to  claim 27 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         34 . The method according to  claim 28 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         35 . The method according to  claim 29 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         36 . The method according to  claim 30 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         37 . The method according to  claim 31 , wherein the nicotinic acid is dosed in the evening or at night.

Join the waitlist — get patent alerts

Track US2007237819A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.